10x Genomics, Inc.
10x Genomics, Inc. Fundamental Analysis
10x Genomics, Inc. (TXG) shows moderate financial fundamentals with a PE ratio of -119.43, profit margin of -3.55%, and ROE of -2.86%. The company generates $0.6B in annual revenue with moderate year-over-year growth of 5.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 30.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TXG's fundamental strength across five key dimensions:
Efficiency Score
WeakTXG struggles to generate sufficient returns from assets.
Valuation Score
ExcellentTXG trades at attractive valuation levels.
Growth Score
ExcellentTXG delivers strong and consistent growth momentum.
Financial Health Score
ExcellentTXG maintains a strong and stable balance sheet.
Profitability Score
WeakTXG struggles to sustain strong margins.
Key Financial Metrics
Is TXG Expensive or Cheap?
P/E Ratio
TXG trades at -119.43 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, TXG's PEG of -0.47 indicates potential undervaluation.
Price to Book
The market values 10x Genomics, Inc. at 3.32 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -524.29 times EBITDA. This is generally considered low.
How Well Does TXG Make Money?
Net Profit Margin
For every $100 in sales, 10x Genomics, Inc. keeps $-3.55 as profit after all expenses.
Operating Margin
Core operations generate -6.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.86 in profit for every $100 of shareholder equity.
ROA
10x Genomics, Inc. generates $-2.23 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
10x Genomics, Inc. produces operating cash flow of $126.49M, showing steady but balanced cash generation.
Free Cash Flow
10x Genomics, Inc. generates strong free cash flow of $120.91M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.95 in free cash annually.
FCF Yield
TXG converts 4.54% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-119.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.47
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.19
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.10
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.90
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.03
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.04
vs 25 benchmark
How TXG Stacks Against Its Sector Peers
| Metric | TXG Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -119.43 | 28.62 | Better (Cheaper) |
| ROE | -2.86% | 783.00% | Weak |
| Net Margin | -3.55% | -48181.00% (disorted) | Weak |
| Debt/Equity | 0.10 | 0.39 | Strong (Low Leverage) |
| Current Ratio | 5.90 | 4.12 | Strong Liquidity |
| ROA | -2.23% | -21914.00% (disorted) | Weak |
TXG outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews 10x Genomics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
74.41%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
93.49%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
150.63%
Industry Style: Defensive, Growth, Innovation
High Growth